Company / R&D Expense
Revvity R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$215.8M
FY2025
5-year range
$196.8M / $221.6M
FY2021-FY2025
Trend
+9.7%
vs FY2024
Sector context
#35 of 110
Health Care
What the data says
At $216M, Revvity's r&d expense ranks #35 of 110 in the Health Care sector. R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $216M.
Based on SEC 10-K filings.
$216M in FY2025 with a 5-year CAGR of +8.1%.
Remained stable around $216M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.9%
- 5-Year CAGR
- +8.1%
- 10-Year CAGR
- -
Sector benchmark
#35 of 110 in Health CareTop 32% of 110This company $215.8M Sector average $298.2M
▼
-27.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +8.1%, indicating consistent growth.
- In FY2025, r&d expense increased 9.7% year-over-year.
- Ranks #35 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2022.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $215.8M | +9.7% |
| FY2024 | $196.8M | -9.1% |
| FY2023 | $216.6M | -2.3% |
| FY2022 | $221.6M | +10.6% |
| FY2021 | $200.3M | +36.8% |
| FY2020 | $146.4M | -22.7% |
| FY2019 | $189.3M | -2.4% |
| FY2018 | $194.0M | +39.1% |
| FY2017 | $139.5M | +12.3% |
| FY2016 | $124.2M | +10.3% |
As of FY2025 · SEC 10-K · Updated Mar 14, 2026